JP2021138695A - カルコブトロールの製造方法 - Google Patents
カルコブトロールの製造方法 Download PDFInfo
- Publication number
- JP2021138695A JP2021138695A JP2021034941A JP2021034941A JP2021138695A JP 2021138695 A JP2021138695 A JP 2021138695A JP 2021034941 A JP2021034941 A JP 2021034941A JP 2021034941 A JP2021034941 A JP 2021034941A JP 2021138695 A JP2021138695 A JP 2021138695A
- Authority
- JP
- Japan
- Prior art keywords
- calcobutrol
- butrol
- producing
- general formula
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- GCLKDXFGQNCFQW-CTHHTMFSSA-L calcium 2-[4,10-bis(carboxylatomethyl)-7-[(2R,3S)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate hydron Chemical compound [H+].[Ca+2].OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GCLKDXFGQNCFQW-CTHHTMFSSA-L 0.000 title claims abstract description 31
- 229950006450 calcobutrol Drugs 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title abstract description 20
- JZNZSKXIEDHOBD-HUUCEWRRSA-N 2-[4,10-bis(carboxymethyl)-7-[(2r,3s)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC[C@@H](O)[C@@H](CO)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 JZNZSKXIEDHOBD-HUUCEWRRSA-N 0.000 claims abstract description 22
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims abstract description 20
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 12
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940106681 chloroacetic acid Drugs 0.000 claims abstract description 9
- GEKNCWQQNMEIMS-UHFFFAOYSA-N 4,4-dimethyl-3,5,8-trioxabicyclo[5.1.0]octane Chemical compound C1OC(C)(C)OCC2OC21 GEKNCWQQNMEIMS-UHFFFAOYSA-N 0.000 claims abstract description 7
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 claims abstract description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- ZPDFIIGFYAHNSK-CTHHTMFSSA-K 2-[4,10-bis(carboxylatomethyl)-7-[(2r,3s)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) Chemical compound [Gd+3].OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-CTHHTMFSSA-K 0.000 abstract description 8
- 229960003411 gadobutrol Drugs 0.000 abstract description 8
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract description 2
- 239000002616 MRI contrast agent Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000008213 purified water Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 6
- 229910052688 Gadolinium Inorganic materials 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- 238000001728 nano-filtration Methods 0.000 description 4
- 239000001273 butane Substances 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- RRBYUSWBLVXTQN-UHFFFAOYSA-N tricyclene Chemical compound C12CC3CC2C1(C)C3(C)C RRBYUSWBLVXTQN-UHFFFAOYSA-N 0.000 description 3
- RRBYUSWBLVXTQN-VZCHMASFSA-N tricyclene Natural products C([C@@H]12)C3C[C@H]1C2(C)C3(C)C RRBYUSWBLVXTQN-VZCHMASFSA-N 0.000 description 3
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 2
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- ZPDFIIGFYAHNSK-UHFFFAOYSA-K gadobutrol Chemical compound [Gd+3].OCC(O)C(CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-UHFFFAOYSA-K 0.000 description 2
- -1 gadolinium cations Chemical class 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 2
- 229940039790 sodium oxalate Drugs 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 2
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- DGPUYHMCOANORE-UHFFFAOYSA-L calcium;acetic acid;diacetate Chemical compound [Ca+2].CC(O)=O.CC([O-])=O.CC([O-])=O DGPUYHMCOANORE-UHFFFAOYSA-L 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical compound C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- NIFHFRBCEUSGEE-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O NIFHFRBCEUSGEE-UHFFFAOYSA-N 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
1,4,7,10−テトラアザシクロドデカン(100g,1eq)、塩化リチウム(29.55g,1.14eq)、4,4−ジメチル−3,5,8−トリオキサビシクロ[5.1.0]オクタン(83.75g,1eq)、およびイソプロピルアルコール(219.6g,2.2vol)を反応器に投入し、85〜95℃まで昇温させて反応を行った。反応が終わった後、メチルtert−ブチルエーテル830.49gを投入し、20〜25℃で1時間攪拌した後、ろ過し、メチルtert−ブチルエーテル79.56gで洗浄した。ろ液を減圧濃縮した後、精製水642.5gを投入した。温度を50℃まで昇温させた後、クロロ酢酸(139.1g,3.7eq)を入れた。40%のNaOHを滴加してpH9〜10を保ちながら75〜85℃で加熱攪拌して反応を終結させ、塩酸14.83gを投入した後、減圧濃縮した。メタノール128.5gを投入して塩をろ過し、ナノろ過(ナノフィルトレーション)を行った。その後、弱い塩基レジンと弱酸性レジンとをそれぞれ650gずつ樹脂搭に入れ、反応液を10回処理した後、減圧濃縮して、透明な液状のブトロール100gを得た(歩留まり率:38.26重量%、純度:99.8%、水分:11.2%)。
前記実施例1において製造したブトロール50.0g、カルシウムカーボネート9.87g、および精製水200mlを反応器に投入した後、75℃まで昇温させて3時間攪拌した後、冷却してろ過した。濃縮後に精製水50mlを投入し、40℃まで昇温させてアセトン600mlを投入した。結晶が生成されれば、20℃まで冷却した後、生成された結晶をろ過し且つ乾燥させて、白色のカルコブトロール固体46.12g(歩留まり率:85.0%)を得た。
前記実施例1において製造したブトロール50.0g、カルシウムカーボネート9.87g、および精製水200mlを反応器に投入した後、75℃まで昇温させて3時間攪拌した後、冷却してろ過した。濃縮後に温度を60℃まで昇温させた後、無水エタノール200mlを入れ、固体が生成されれば、濃縮し、水分が3%になるまで無水エタノールを入れてさらに濃縮した。水分が3%になると、20℃まで冷却した後、生成された結晶をろ過し且つ乾燥させて、白色のカルコブトロール固体49.37g(歩留まり率:91.0%)を得た。
Claims (7)
- 前記ブトロールの製造に際して、pHが8〜12である、請求項1に記載のカルコブトロールの製造方法。
- 前記ブトロールは、ナノフィルターを用いて精製する、請求項1に記載のカルコブトロールの製造方法。
- 前記カルシウムイオンは、カルシウムカーボネート、カルシウムヒドロキシド、カルシウムクロリドおよびこれらの混合物よりなる群から選ばれ、前記カルシウムイオンの含量は、ブトロールに対して、0.95〜1.05当量である、請求項1に記載のカルコブトロールの製造方法。
- 前記クロロ酢酸の使用量は、カルコブトロール中間体に対して、3.0〜4.5当量である、請求項1に記載のカルコブトロールの製造方法。
- 前記4,4−ジメチル−3,5,8−トリオキサビシクロ[5,1,0]オクタンの使用量は、シクレン−塩化リチウム錯体に対して、1.0〜1.5当量である、請求項1に記載のカルコブトロールの製造方法。
- 前記カルコブトロールを得るステップにおいて、メタノール、エタノール、イソプロパノールおよびアセトンよりなる群から選ばれる結晶化溶媒を用いて結晶化させる、請求項1に記載のカルコブトロールの製造方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200028549A KR20210112910A (ko) | 2020-03-06 | 2020-03-06 | 가도부트롤 주사제 제조를 위한 부형제인 칼코부트롤의 제조 방법 |
KR10-2020-0028549 | 2020-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021138695A true JP2021138695A (ja) | 2021-09-16 |
Family
ID=74853569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021034941A Ceased JP2021138695A (ja) | 2020-03-06 | 2021-03-05 | カルコブトロールの製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210276961A1 (ja) |
EP (1) | EP3875453A1 (ja) |
JP (1) | JP2021138695A (ja) |
KR (1) | KR20210112910A (ja) |
CN (1) | CN113354594A (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210114742A (ko) * | 2020-03-11 | 2021-09-24 | 주식회사 엔지켐생명과학 | 칼테리돌의 제조방법 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002508755A (ja) * | 1997-06-02 | 2002-03-19 | シェリング アクチェンゲゼルシャフト | モノ−及び1、7−ビス−n−ヒドロキシアルキル−シクレン並びにそのリチウム塩錯体の製造 |
JP2004515545A (ja) * | 2000-12-15 | 2004-05-27 | シエーリング アクチエンゲゼルシヤフト | N−(1−ヒドロキシメチル−2,3−ジヒドロキシプロピル)−1,4,7−トリスカルボキシメチル−1,4,7,10−テトラアザシクロドデカンのリチウム錯体、その製造及び使用 |
JP2013510117A (ja) * | 2009-11-04 | 2013-03-21 | バイエル・ファルマ・アクチェンゲゼルシャフト | カルコブトロールの製造方法 |
JP2017530971A (ja) * | 2014-09-17 | 2017-10-19 | エスティ ファーム カンパニー リミテッド | カルコブトロールの製造方法 |
KR20190025131A (ko) * | 2017-08-29 | 2019-03-11 | 주식회사 엔지켐생명과학 | 가도부트롤 중간체 및 이를 이용한 가도부트롤의 제조 방법 |
KR20190088793A (ko) * | 2018-01-19 | 2019-07-29 | 주식회사 엔지켐생명과학 | 칼코부트롤의 제조방법 |
JP2019534869A (ja) * | 2016-09-27 | 2019-12-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | カルコブトロールの変態aの結晶形態を製造する方法 |
WO2020012372A1 (en) * | 2018-07-10 | 2020-01-16 | Biophore India Pharmaceuticals Pvt. Ltd | Process for the preparation of 2,2',2''-(10-((2r,3s)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106187930B (zh) * | 2016-07-12 | 2018-10-19 | 嘉实(湖南)医药科技有限公司 | 高纯度考布曲钙的制备方法 |
-
2020
- 2020-03-06 KR KR1020200028549A patent/KR20210112910A/ko not_active Application Discontinuation
-
2021
- 2021-03-01 EP EP21160054.9A patent/EP3875453A1/en not_active Withdrawn
- 2021-03-04 CN CN202110242281.1A patent/CN113354594A/zh active Pending
- 2021-03-05 JP JP2021034941A patent/JP2021138695A/ja not_active Ceased
- 2021-03-05 US US17/193,592 patent/US20210276961A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002508755A (ja) * | 1997-06-02 | 2002-03-19 | シェリング アクチェンゲゼルシャフト | モノ−及び1、7−ビス−n−ヒドロキシアルキル−シクレン並びにそのリチウム塩錯体の製造 |
JP2004515545A (ja) * | 2000-12-15 | 2004-05-27 | シエーリング アクチエンゲゼルシヤフト | N−(1−ヒドロキシメチル−2,3−ジヒドロキシプロピル)−1,4,7−トリスカルボキシメチル−1,4,7,10−テトラアザシクロドデカンのリチウム錯体、その製造及び使用 |
JP2013510117A (ja) * | 2009-11-04 | 2013-03-21 | バイエル・ファルマ・アクチェンゲゼルシャフト | カルコブトロールの製造方法 |
JP2017530971A (ja) * | 2014-09-17 | 2017-10-19 | エスティ ファーム カンパニー リミテッド | カルコブトロールの製造方法 |
JP2019534869A (ja) * | 2016-09-27 | 2019-12-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | カルコブトロールの変態aの結晶形態を製造する方法 |
KR20190025131A (ko) * | 2017-08-29 | 2019-03-11 | 주식회사 엔지켐생명과학 | 가도부트롤 중간체 및 이를 이용한 가도부트롤의 제조 방법 |
KR20190088793A (ko) * | 2018-01-19 | 2019-07-29 | 주식회사 엔지켐생명과학 | 칼코부트롤의 제조방법 |
WO2020012372A1 (en) * | 2018-07-10 | 2020-01-16 | Biophore India Pharmaceuticals Pvt. Ltd | Process for the preparation of 2,2',2''-(10-((2r,3s)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes |
Also Published As
Publication number | Publication date |
---|---|
KR20210112910A (ko) | 2021-09-15 |
US20210276961A1 (en) | 2021-09-09 |
CN113354594A (zh) | 2021-09-07 |
EP3875453A1 (en) | 2021-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7071760B2 (ja) | カルコブトロールの製造方法 | |
CN108299322B (zh) | 一种制备钆布醇的方法 | |
JP2013531643A (ja) | 結晶質3,6,9−トリアザ−3,6,9−トリス(カルボキシメチル)−4−(4−エトキシベンジル)ウンデカン二酸を調製する方法及びプリモビスト(Primovist)(登録商標)を製造するための方法 | |
CN105037288B (zh) | 一种布醇的制备方法 | |
JP2021138695A (ja) | カルコブトロールの製造方法 | |
JP6967143B2 (ja) | ガドブトロール中間体及びこれを用いたガドブトロールの製造方法 | |
KR102167614B1 (ko) | 가도부트롤의 제조방법 | |
JP7272710B2 (ja) | カルコブトロールの製造方法 | |
JP7032550B2 (ja) | ガドテリドール中間体及びこれを利用したガドテリドール製造方法 | |
JP7157195B2 (ja) | カルテリドールの製造方法 | |
RU2779668C1 (ru) | Способ получения калькобутрола | |
KR102445756B1 (ko) | 가도테레이트 메글루민 중간체인 가도테릭산 및 이를 이용한 가도테레이트 메글루민 제조 방법 | |
CN113272284B (zh) | 制备考布曲钙的方法 | |
KR100877134B1 (ko) | 아캄프로세이트 칼슘의 제조방법 | |
JP4402500B2 (ja) | イオパミドールの精製方法 | |
TR2021010179T2 (tr) | Kalkobutrol hazirlamaya yöneli̇k yöntem | |
JPS642581B2 (ja) | ||
JP2018039755A (ja) | ナトリウム2α−メチル−2β−(1,2,3−トリアゾール−1−イル)−メチルペナム−3α−カルボン酸1,1−ジオキシド一水和物結晶の製造方法 | |
JP2018039756A (ja) | ナトリウム2α−メチル−2β−(1,2,3−トリアゾール−1−イル)−メチルペナム−3α−カルボン酸1,1−ジオキシド一水和物結晶の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210305 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220420 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220531 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20220927 |